Comparing Orion OYJ (OTCMKTS:ORINY) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) and Orion OYJ (OTCMKTS:ORINY) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Dividends

Shionogi & Co., Ltd. Unsponsored ADR pays an annual dividend of $0.14 per share and has a dividend yield of 1.6%. Orion OYJ pays an annual dividend of $0.38 per share and has a dividend yield of 0.8%. Shionogi & Co., Ltd. Unsponsored ADR pays out 14.0% of its earnings in the form of a dividend. Orion OYJ pays out 15.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Shionogi & Co., Ltd. Unsponsored ADR is clearly the better dividend stock, given its higher yield and lower payout ratio.

Insider & Institutional Ownership

1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, Orion OYJ has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500.

Earnings & Valuation

This table compares Shionogi & Co., Ltd. Unsponsored ADR and Orion OYJ”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shionogi & Co., Ltd. Unsponsored ADR	$3.32 billion	4.51	$1.35 billion	$1.00	8.80
Orion OYJ	$2.14 billion	6.44	$566.04 million	$2.43	20.08

Shionogi & Co., Ltd. Unsponsored ADR has higher revenue and earnings than Orion OYJ. Shionogi & Co., Ltd. Unsponsored ADR is trading at a lower price-to-earnings ratio than Orion OYJ, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Shionogi & Co., Ltd. Unsponsored ADR and Orion OYJ’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shionogi & Co., Ltd. Unsponsored ADR	46.67%	16.13%	12.09%
Orion OYJ	28.52%	50.37%	30.65%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Shionogi & Co., Ltd. Unsponsored ADR and Orion OYJ, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shionogi & Co., Ltd. Unsponsored ADR	0	1	0	2	3.33
Orion OYJ	0	1	1	0	2.50

Summary

Shionogi & Co., Ltd. Unsponsored ADR beats Orion OYJ on 9 of the 15 factors compared between the two stocks.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.